Summit Therapeutics/$SMMT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Summit Therapeutics
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Ticker
$SMMT
Sector
Primary listing
Employees
265
Headquarters
Website
SMMT Metrics
BasicAdvanced
$11bn
-
-$1.59
-1.26
-
Price and volume
Market cap
$11bn
Beta
-1.26
52-week high
$30.98
52-week low
$12.55
Average daily volume
5m
Financial strength
Current ratio
7.405
Quick ratio
7.191
Long term debt to equity
3.088
Total debt to equity
3.67
Profitability
EBITDA (TTM)
-1,222.62
Management effectiveness
Return on assets (TTM)
-148.15%
Return on equity (TTM)
-270.95%
Valuation
Price to book
19.42
Price to tangible book (TTM)
19.49
Price to free cash flow (TTM)
-26.859
Free cash flow yield (TTM)
-3.72%
Free cash flow per share (TTM)
-0.509
Growth
Earnings per share change (TTM)
369.19%
3-year earnings per share growth (CAGR)
-11.23%
What the Analysts think about SMMT
Analyst ratings (Buy, Hold, Sell) for Summit Therapeutics stock.
SMMT Financial Performance
Revenues and expenses
SMMT Earnings Performance
Company profitability
SMMT News
AllArticlesVideos
Summit Therapeutics Q2 Earnings Call Highlights
MarketBeat·3 days ago
Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
Business Wire·5 days ago
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug
Benzinga·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.